Edesa Biotech, INC 8-K filings

Edesa Biotech announced a $3.5 million private placement financing, including participation from its CEO, to advance its vitiligo program and for general corporate purposes.

Edesa Biotech announced favorable exploratory clinical data for paridiprubart in patients with acute kidney injury and respiratory distress.

Edesa Biotech's CEO will receive 90% of his base salary in restricted stock units, a significant increase from the previous 50% equity component.

Edesa Biotech announced its fiscal second quarter 2026 financial results, highlighting progress in its dermatology and respiratory programs, with a focus on upcoming clinical studies.

Edesa Biotech announced positive additional data from its Phase 3 study of paridiprubart, demonstrating a statistically significant reduction in 28-day mortality across a broader patient population.

Edesa Biotech, Inc. increased its at-the-market offering capacity to $2,262,508 for common shares, signaling continued capital raising efforts.

Edesa Biotech announced fiscal year 2025 financial results, highlighted by positive Phase 3 data for paridiprubart and progress in its vitiligo program.

Edesa Biotech announced positive Phase 3 results for paridiprubart (EB05) in Acute Respiratory Distress Syndrome, demonstrating significant reductions in mortality and improved clinical outcomes.

Edesa Biotech has amended its multi-year contribution agreement with the Government of Canada, shifting its clinical focus for EB05 to general ARDS and extending project timelines.

Edesa Biotech, Inc. filed a prospectus supplement to offer and sell up to $4,006,544 in common shares through an at-the-market offering program.

Edesa Biotech announced its fiscal third-quarter 2025 financial results, reporting a net loss in line with expectations and significant progress in its lead vitiligo drug candidate, EB06.

Edesa Biotech, Inc. announced that its shareholders approved all proposals at the 2025 Annual General and Special Meeting, including the re-election of its board of directors and a significant amendment to its 2019 Equity Incentive Compensation Plan.

Edesa Biotech announces its Q2 2025 financial results, highlighting a shift in focus towards its vitiligo drug candidate EB06 and a recent $15 million equity financing.

Edesa Biotech announces the appointment of Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux, who will transition to a senior financial advisor role.

Edesa Biotech announced its Q1 2025 financial results and provided an update on the development of EB06 for vitiligo, with plans to submit data to the FDA in mid-2025.

Edesa Biotech announces a $15 million private placement, led by Velan Capital, to fund the Phase 2 clinical study of EB06 for nonsegmental vitiligo and for general corporate purposes.

Edesa Biotech announced its fiscal year 2024 results, highlighting a pivot towards government-funded research and a decrease in operating expenses.

Edesa Biotech has entered into a securities purchase agreement with an entity controlled by its CEO, Pardeep Nijhawan, for a strategic investment of up to $5 million, including an initial $1.5 million, and terminated a prior credit agreement.

Edesa Biotech has entered into a new at-the-market offering agreement with H.C. Wainwright & Co., while terminating its previous agreement with Canaccord Genuity LLC.

Edesa Biotech announced its financial results for the three and nine months ended June 30, 2024, highlighting a decrease in operating expenses and progress in its clinical programs.

Edesa Biotech's drug candidate, paridiprubart (EB05), has been chosen by BARDA for evaluation in a U.S. government-funded clinical study for Acute Respiratory Distress Syndrome (ARDS).

Edesa Biotech's shareholders approved an increase in shares available under the 2019 Equity Incentive Plan and elected directors at their 2024 annual meeting.

Edesa Biotech announced its financial results for the three and six months ended March 31, 2024, alongside updates on its clinical development programs, including a Phase 3 study for its ARDS drug candidate.

Edesa Biotech announced its financial results for the first fiscal quarter of 2024, highlighting a decrease in operating expenses, government funding, and progress in its clinical programs.